So far so good on 510(k) review in US
This article was originally published in SRA
Executive Summary
The general reaction to yesterday's release by the Food and Drug Administration of its keenly awaited road map for the regulatory tightening of the 510(k) premarket notification programme was one of mild relief, tinged with the suspicion that it's not all over yet.